Scarica l'app Stockscreener
2.33
0.43%
0.01
Precedente Chiudi:
$2.32
Aprire:
$2.31
Volume 24 ore:
920.52K
Relative Volume:
0.97
Capitalizzazione di mercato:
$250.53M
Reddito:
-
Utile/perdita netta:
$-31.64M
Rapporto P/E:
-5.5135
EPS:
-0.4226
Flusso di cassa netto:
$-13.98M
1 W Prestazione:
+2.19%
1M Prestazione:
+40.36%
6M Prestazione:
-45.43%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.275
$2.395
Intervallo di 1 settimana:
$2.1001
$2.395
Portata 52W:
$1.58
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Nome
Nervgen Pharma Corp
Settore
Industria
Telefono
-
Indirizzo
-
Compare NGEN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
2.33 | 189.24M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nervgen Pharma Corp Stock (NGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | H.C. Wainwright | Buy |
Nervgen Pharma Corp Borsa (NGEN) Ultime notizie
What Makes NervGen Pharma (TSXV:NGEN) A Biotech Watchlist Name? - Kalkine Media
NervGen (NGEN) Results Check: Available Metrics Are Broadly in Line for the Current Session; Share Response: The Stock Loses 1.14% in Latest TradingEarnings Surprise Score - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
NervGen Pharma (NGEN) Advances RESTORE Study with FDA Backing, F - GuruFocus
NervGen Pharma (HAM:9UA) Cyclically Adjusted PS Ratio : (As of Aug. 16, 2026) - GuruFocus
NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen - MarketBeat
NervGen Pharma (NGEN) Dips 1.4% to $1.74, Holds Above Key SupportAndrews Pitchfork - dars.gov.et
NGEN: RESTORE Phase 3 trial advances with robust funding and FDA alignment; Q2 net loss widens - TradingView
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates - Caledonian Record
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NervGen Q2 FY26 net loss widens to C$29.2 million - Bitget
NervGen Pharma (NGEN) Institutional Ownership 2026 - MarketBeat
NervGen Pharma (NGEN) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
NGEN Q2'26 Earnings: revenue estimate is 0 USD - TradingView
NervGen Pharma (NGEN) Q3 2025 Earnings: Narrower-than-Expected Loss as Pipeline Development Continues - vinanet.vn
NervGen Pharma (NGEN) Edges Higher to $1.62, Holding Above Key Support LevelBackspread Trade - vinanet.vn
NGEN Q3 2025 Earnings: Narrower Net Loss Brings a 0.99 Percent Positive SurpriseEBITDA Estimate Trend - vinanet.vn
NervGen Pharma (NGEN) Holds Near Support as Price Pullback Tests Key LevelsMoney Flow - dars.gov.et
Oramed Pharmaceuticals Market Sentiment - Benzinga
Nervgen Pharma Ord Shs (NGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nervgen Pharma Ord Shs (NGEN) Balance Sheet - TradingKey
Nervgen Pharma Ord Shs (NGEN) Institutional Confidence - TradingKey
Nervgen Pharma Ord Shs (NGEN) Income Statement - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.640|Chg%:+0.010 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nervgen Pharma Ord Shs (NGEN) Cash Flow - TradingKey
NervGen Pharma Corp. Revenue Breakdown – NASDAQ:NGEN - TradingView
Nervgen Pharma Ord Shs (NGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.630|Chg%:-0.045 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NGEN Q3 2025 Earnings: Narrower Loss Surprises as Clinical Pipeline Progress ContinuesEarnings Weakness Phase - Vinanet
Nervgen Pharma Ord Shs (NGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NervGen Pharma (NGEN) Slips 1.45% as Stock Tests Key Support Near $1.61Descending Triangle - vinanet.vn
NGEN Q3 2025 Earnings: Slight EPS Beat Amid Ongoing Pipeline DevelopmentPre-Earnings Setup - vinanet.vn
Certain Common Shares of NervGen Pharma Corp. are subject to a Lock-Up Agreement Ending on 21-JUL-2026. - marketscreener.com
HC Wainwright Lowers Earnings Estimates for NervGen Pharma - MarketBeat
Stock Ratings | HC Wainwright lowered its price target for NervGen Pharma (NGEN) to $15, with a potential upside of 762.07%; KeyBanc raised its price target for Nvidia (NVDA) to $330 - Sahm
H.C. Wainwright cuts NervGen stock price target to $15 on dilution By Investing.com - Investing.com South Africa
H.C. Wainwright cuts NervGen stock price target to $15 on dilution - Investing.com Nigeria
NGEN Maintains Buy Rating by HC Wainwright & Co. -- Price Target Lowered to $15.00 - GuruFocus
NervGen Pharma (NGEN) Gains Ground: Biotech Stock Holds Above Key SupportRelative Volume - dars.gov.et
NGEN Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Leerink Partners Initiates NervGen Pharma(NGEN.US) With Buy Rating, Announces Target Price $10 - Moomoo
NervGen Pharma (NASDAQ:NGEN) Now Covered by Leerink Partners - MarketBeat
Lobbying Update: $50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed | NGEN Stock News - Quiver Quantitative
If You Invested $1,000 in Nervgen Pharma Corp (NGENF) - Stock Titan
NGEN Q3 2025 Earnings: Narrow EPS Beat Masks Continued Pre-Revenue Stage, Stock Sheds Nearly 7%EPS Consistency Score - dars.gov.et
Breakthrough peptide repairs nerves after spinal cord injury in clinical trial - BioXconomy
NervGen Pharma (NGEN) Q3 2025 Earnings: Small EPS Beat Amid Ongoing Clinical Development and Cash ManagementEarnings Growth Analysis - dars.gov.et
NervGen Pharma(NGEN) Stock Options Chain | Quotes & News - Moomoo
NervGen Pharma Corp. (NGEN) Q3 2025 Earnings: Small EPS Beat as Pipeline Progress Underpins Market Confidence - dars.gov.et
Nervgen Pharma Corp Azioni (NGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):